Neurocentria, Inc.
Clinical trials sponsored by Neurocentria, Inc., explained in plain language.
-
Experimental ADHD drug tested on teens in classroom setting
Disease control TerminatedThis study tested whether a medication called NRCT-101SR could help control ADHD symptoms in teenagers aged 13-17. Researchers compared the drug against a placebo (inactive treatment) over 12 weeks, measuring changes in ADHD symptoms using standard rating scales. The trial was te…
Phase: PHASE2, PHASE3 • Sponsor: Neurocentria, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
ADHD drug combo trial halted early
Disease control TerminatedThis study aimed to see if adding a new medicine (NRCT-101SR) to a standard ADHD drug (NRCT-202XR) works better and is safe for teens. It planned to enroll about 60 teenagers (ages 13-17) with ADHD for a 6-week period. The trial was terminated early, with only 2 participants enro…
Phase: PHASE2 • Sponsor: Neurocentria, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC